134 related articles for article (PubMed ID: 21610636)
1. Blockade of interleukin-6 in murine sepsis revisited: is there an indication for a new therapy in human patients?
Kurdowska A; Krupa A
Crit Care Med; 2011 Jun; 39(6):1582-3. PubMed ID: 21610636
[No Abstract] [Full Text] [Related]
2. Selective blockade of interleukin-6 trans-signaling improves survival in a murine polymicrobial sepsis model.
Barkhausen T; Tschernig T; Rosenstiel P; van Griensven M; Vonberg RP; Dorsch M; Mueller-Heine A; Chalaris A; Scheller J; Rose-John S; Seegert D; Krettek C; Waetzig GH
Crit Care Med; 2011 Jun; 39(6):1407-13. PubMed ID: 21336117
[TBL] [Abstract][Full Text] [Related]
3. [Antibody-Based Drugs and Other Recombinant Proteins for Diagnostics and Therapy of Viral Infections, Autoimmune Diseases and Cancer].
Kuprash DV; Garib FY; Nedospasov SA
Mol Biol (Mosk); 2017; 51(6):883-885. PubMed ID: 29271953
[No Abstract] [Full Text] [Related]
4. p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group.
Abraham E; Glauser MP; Butler T; Garbino J; Gelmont D; Laterre PF; Kudsk K; Bruining HA; Otto C; Tobin E; Zwingelstein C; Lesslauer W; Leighton A
JAMA; 1997 May; 277(19):1531-8. PubMed ID: 9153367
[TBL] [Abstract][Full Text] [Related]
5. Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients.
Abraham E; Laterre PF; Garbino J; Pingleton S; Butler T; Dugernier T; Margolis B; Kudsk K; Zimmerli W; Anderson P; Reynaert M; Lew D; Lesslauer W; Passe S; Cooper P; Burdeska A; Modi M; Leighton A; Salgo M; Van der Auwera P;
Crit Care Med; 2001 Mar; 29(3):503-10. PubMed ID: 11373411
[TBL] [Abstract][Full Text] [Related]
6. Afelimomab led to a modest mortality benefit in patients with severe sepsis and elevated interleukin-6 levels.
Rondon E; Venkataraman R
Crit Care; 2005 Aug; 9(5):E20. PubMed ID: 16277704
[No Abstract] [Full Text] [Related]
7. The blockade of IL-6 signaling in rational drug design.
Adachi Y; Yoshio-Hoshino N; Nishimoto N
Curr Pharm Des; 2008; 14(12):1217-24. PubMed ID: 18473869
[TBL] [Abstract][Full Text] [Related]
8. The effect of sRAGE-Fc fusion protein attenuates inflammation and decreases mortality in a murine cecal ligation and puncture model.
Jeong SJ; Lim BJ; Park S; Choi D; Kim HW; Ku NS; Han SH; Kim CO; Choi JY; Song YG; Kim JM
Inflamm Res; 2012 Nov; 61(11):1211-8. PubMed ID: 22777145
[TBL] [Abstract][Full Text] [Related]
9. Blocking interleukin-6 activity with chimeric anti-IL6 monoclonal antibodies in multiple myeloma: effects on soluble IL6 receptor and soluble gp130.
Van Zaanen HC; Lokhorst HM; Aarden LA; Rensink HJ; Warnaar SO; Van Oers MH
Leuk Lymphoma; 1998 Nov; 31(5-6):551-8. PubMed ID: 9922045
[TBL] [Abstract][Full Text] [Related]
10. Discovery and characterization of olokizumab: a humanized antibody targeting interleukin-6 and neutralizing gp130-signaling.
Shaw S; Bourne T; Meier C; Carrington B; Gelinas R; Henry A; Popplewell A; Adams R; Baker T; Rapecki S; Marshall D; Moore A; Neale H; Lawson A
MAbs; 2014; 6(3):774-82. PubMed ID: 24670876
[TBL] [Abstract][Full Text] [Related]
11. Immune modulation and sepsis.
Karzai W; Reinhart K
Int J Clin Pract; 1997 Jun; 51(4):232-7. PubMed ID: 9287265
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-1 blockade attenuates mediator release and dysregulation of the hemostatic mechanism during human sepsis.
Boermeester MA; van Leeuwen PA; Coyle SM; Wolbink GJ; Hack CE; Lowry SF
Arch Surg; 1995 Jul; 130(7):739-48. PubMed ID: 7611862
[TBL] [Abstract][Full Text] [Related]
13. Astrocyte response to IFN-γ limits IL-6-mediated microglia activation and progressive autoimmune encephalomyelitis.
Savarin C; Hinton DR; Valentin-Torres A; Chen Z; Trapp BD; Bergmann CC; Stohlman SA
J Neuroinflammation; 2015 Apr; 12():79. PubMed ID: 25896970
[TBL] [Abstract][Full Text] [Related]
14. Pathogenic role of interleukin-6 in the development of sepsis. Part II: Significance of anti-interleukin-6 and anti-soluble interleukin-6 receptor-alpha antibodies in a standardized murine contact burn model.
Pallua N; Low JF; von Heimburg D
Crit Care Med; 2003 May; 31(5):1495-501. PubMed ID: 12771624
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic blockade of interleukin-6 in chronic inflammatory disease.
Yamamoto K; Rose-John S
Clin Pharmacol Ther; 2012 Apr; 91(4):574-6. PubMed ID: 22434029
[No Abstract] [Full Text] [Related]
16. Preparation and evaluation of human-murine chimeric antibody against protective antigen of Bacillus anthracis.
Hao L; Zheng F; Xiong S; Hu D; Lv H; Tang Q; Yang J; Feng Z; Wang C; Zhu J
Int J Mol Sci; 2014 Oct; 15(10):18496-507. PubMed ID: 25318053
[TBL] [Abstract][Full Text] [Related]
17. Modulation of macrophage hyperactivity improves survival in a burn-sepsis model.
O'Riordain MG; Collins KH; Pilz M; Saporoschetz IB; Mannick JA; Rodrick ML
Arch Surg; 1992 Feb; 127(2):152-7; discussion 157-8. PubMed ID: 1540091
[TBL] [Abstract][Full Text] [Related]
18. [Engineering Antibodies as Drugs: Principles and Practice].
Lugovskoy AA
Mol Biol (Mosk); 2017; 51(6):886-898. PubMed ID: 29271954
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic effects of interleukin-6 blockade in a murine model of polymyositis that does not require interleukin-17A.
Okiyama N; Sugihara T; Iwakura Y; Yokozeki H; Miyasaka N; Kohsaka H
Arthritis Rheum; 2009 Aug; 60(8):2505-12. PubMed ID: 19644888
[TBL] [Abstract][Full Text] [Related]
20. Importance of underlying mechanism and genotype on outcome of sepsis trials.
McIntyre L; Walley KR
Crit Care Med; 2001 Mar; 29(3):677-9. PubMed ID: 11373447
[No Abstract] [Full Text] [Related]
[Next] [New Search]
